Novartis Exits Indian Arm: Sells 70.68% Stake for ₹1,446 Cr

Novartis AG Divests Stake in Indian Listed Entity

Swiss multinational pharmaceutical corporation Novartis AG has announced its decision to sell its entire 70.68% stake in its publicly listed Indian subsidiary, Novartis India Limited. The stake will be acquired by a consortium led by the private equity firm ChrysCapital for a total consideration of ₹1,446 crore, which is approximately $159 million. This move marks a significant strategic shift for Novartis, aligning with its global objective to streamline operations and focus on innovative medicines. The transaction, which was announced on Friday, is expected to be completed in the third quarter of 2026, pending regulatory approvals and the fulfillment of customary closing conditions.

Details of the Transaction and Open Offer

The agreement involves the sale of 1,74,50,680 shares held by Novartis AG to a buyer group that includes WaveRise Investments, ChrysCapital Fund X, Two Infinity Partners, and other entities under the ChrysCapital umbrella. As per Indian takeover regulations, the acquisition has triggered a mandatory open offer to the public shareholders of Novartis India. The ChrysCapital-led consortium has announced an offer to purchase an additional 26% of the company's voting share capital. The offer price is set at ₹860.64 per share, which would amount to approximately ₹552.49 crore if fully subscribed. This price represented a 3.6% premium over the stock's closing price on the day before the announcement.

Market Reacts Positively to the Announcement

Investors responded with strong optimism to the news of the divestment. On the day of the announcement, shares of Novartis India Limited surged, hitting the 20% upper circuit limit in intraday trading. The stock price climbed to ₹996.50 on the BSE, a significant jump from its previous close. This positive market reaction occurred despite the open offer price being lower than the market price, indicating investor confidence in the company's future under new ownership. The sharp rise in the stock price widely outperformed the benchmark Sensex, which saw only a minor gain on the same day.

A Strategic Realignment for Novartis

The decision to sell the stake is the outcome of a strategic review initiated by Novartis AG in February 2024. The company has been globally restructuring its operations to transform into a 'pure-play innovative medicines company.' This strategy involves prioritizing patented therapies in high-growth areas like oncology and cardio-renal-metabolic diseases. By divesting its stake in the listed Indian entity, which focuses on established brands, Novartis AG is sharpening its global footprint and concentrating resources on its core research and development-driven business model.

Novartis's Continued Commitment to India

It is important to note that this transaction does not signify a complete exit for Novartis from the Indian market. The Swiss drugmaker will maintain a significant presence through its wholly-owned subsidiary, Novartis Healthcare Private Limited (NHPL). This entity houses the company's commercial operations, the Novartis Corporate Center in Hyderabad, and extensive research and development teams. NHPL currently supports clinical trials across more than 300 sites in India and employs over 9,000 associates, which is about 11% of Novartis's global workforce. This underscores India's continued importance to Novartis's global R&D and digital health initiatives.

Challenges and Performance of Novartis India

The stake sale comes at a time when Novartis India has been facing declining sales. According to data from market tracker PharmaTrac, the company's 12-month sales value saw a gradual decline from ₹655 crore as of December 2022 to ₹493 crore by the end of December 2025. A key factor in this decline has been the performance of its blockbuster heart failure drug, Vymada. Sales of Vymada fell from ₹258 crore to ₹180 crore over the same period, largely due to the drug going off-patent and facing increased competition from generic alternatives.

ChrysCapital's Strategic Acquisition

For ChrysCapital, one of India's largest private equity firms, this acquisition is a landmark deal. It represents the firm's first majority stake purchase in the Indian pharmaceutical sector. ChrysCapital has a strong investment history in healthcare, with stakes in companies such as Intas Pharma, Eris Lifesciences, and Corona Remedies. This transaction provides the PE firm with a controlling position in an established company with a well-known portfolio of products, including the popular painkiller Voveran.

Key Transaction Details

The Path Forward

Following the completion of the deal, the ChrysCapital-led consortium will be classified as the new promoters of Novartis India Limited. As part of the agreement, the company is required to change its name and remove any branding references to the Novartis group within 120 days of the transaction's closing. The deal will reshape the future of Novartis India, placing it under new leadership focused on navigating the competitive landscape of the Indian pharmaceutical market. The transaction is poised to be a strategic success for both parties, allowing Novartis AG to focus on innovation while ChrysCapital expands its footprint in the healthcare sector.